Novartis inks second molecular glue partnership with Orionis, $40M upfront

Novartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million.

The agreement also provides for milestone payments that could total up to $1.4 billion, reflecting the companies' expectations for future development and commercialization.

The partnership builds on an existing collaboration between the Swiss drugmaker and the Boston based biotech, signaling Novartis' continued investment in novel drug discovery platforms.